Effect of splenectomy on neurological function and prognosis in patients with hepatolenticular degeneration and hypersplenism

Abstract

Abstract: Objective To explore the impact of splenectomy on neurological function and prognosis in patients with hepatolenticular degeneration and hypersplenism, and to provide a basis for the management of patients with hepatolenticular degeneration and hypersplenism. Methods From January 2020 to March 2023, 63 patients with hepatolenticular degeneration and hypersplenism were admitted to the hospital. According to whether the patients received splenectomy treatment after admission, the patients were divided into a splenectomy group (n=32) and a non-splenectomy group (n=31). The baseline data, post-treatment neurological function and post-treatment liver function of the two groups were compared. Results The difference in the baseline data of the two groups is not statistically significant (P>0.05).The proportion of abnormal motor function and mental function of the patients in the splenectomy group after treatment were 6.3%, 3.1% and 3.1% respectively, which were significantly lower than those of patients in the non-splenectomy group [19.4%, 12.9% and 16.1% (P<0.05)]. The proportion of Child-Pugh A grade after treatment in the splenectomy group was 81.3%, which was significantly higher than that of the patients in the non-splenectomy group (48.4%). The proportion of Child-Pugh grade B, ALT level, and AST level after treatment were and ALP levels were 6.3%, 65 (6,107) U/L, 48 (3,89) U/L and 90 (57,126) U/L respectively, which were significantly lower than those in the non-splenectomy group [22.6%, 136 (13,546) U/L, 94 (32,637) U/L and 120 (70,382) U/L(P<0.05)].In terms of prognosis, 2 patients died in the splenectomy group and 6 patients died in the non-splenectomy group. Conclusion Splenectomy can significantly improve splenic function, neurological function and prognostic outcomes in hepatolenticular degeneration.

Key words: Splenectomy, Hepatolenticular degeneration, Hypersplenism

ZHAO Guang-long, HU Ming, WANG Xiao-dong. Effect of splenectomy on neurological function and prognosis in patients with hepatolenticular degeneration and hypersplenism[J]. Chinese Hepatolgy, 2026, 31(3): 424-427.

References

[1] Peng H, Li Z, Zhang W, et al. Changes in hepatic function after splenectomy for hepatolenticular degeneration, cirrhosis, and hypersplenism[J]. Am Surg, 2023: 31348221114041.
[2] Rab M A E, Meerveld-Eggink A, van Velzen-Blad H, et al. Persistent changes in circulating white blood cell populations after splenectomy[J]. Int J Hematol, 2018, 107(2):157-165.
[3] Zheng Z, Yu Q, Peng H, et al. Nomogram-based prediction of portal vein system thrombosis formation after splenectomy in patients with hepatolenticular degeneration[J]. Front Med (Lausanne), 2023, 10: 1103223.
[4] Sun X, Zhang X, Yan H, et al. Protective effect of curcumin on hepatolenticular degeneration through copper excretion and inhibition of ferroptosis[J]. Phytomedicine, 2023, 113: 154539.
[5] Yin F, Nian M, Wang N, et al. Protective mechanism of gandou decoction in a copper-laden hepatolenticular degeneration model: in vitro pharmacology and cell metabolomics[J]. Front Pharmacol, 2022, 13: 848897.
[6] Xu R, Liang J, Cheng M, et al. Liver and urine metabolomics reveal the protective effect of gandou decoction in copper-laden hepatolenticular degeneration model rats[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2021, 1179: 122844.
[7] Wang S T, Feng H, Peng H, et al. Platelet safety range before splenectomy for hypersplenism: based on 244 cases of splenectomy in hepatolenticular degeneration patients[J]. Acta Gastroenterol Belg, 2021, 84(1): 51-56.
[8] Wang N, Cheng M, Zhang X, et al. Gandou decoction decreases copper levels and alleviates hepatic injury in copper-laden hepatolenticular degeneration model rats[J]. Front Pharmacol, 2020, 11: 582390.
[9] Zhang J, Ma Y, Xie D, et al. Differentially expressed lncrnas in liver tissues of tx mice with hepatolenticular degeneration[J]. Sci Rep, 2021, 11(1): 1377.
[10] Shen Y, Guo B, Wang L, et al. Significance of amylase monitoring in peritoneal drainage fluid after splenectomy: a clinical analysis of splenectomy in 167 patients with hepatolenticular degeneration[J]. Am Surg, 2020, 86(4): 334-340.
[11] Cheng M, Wu H, Wu H, et al. Metabolic profiling of copper-laden hepatolenticular degeneration model rats and the interventional effects of gandou decoction using uplc-q-tof/ms[J]. J Pharm Biomed Anal, 2019, 164: 187-195.
[12] Zhang D. A clinical study of bone mesenchymal stem cells for the treatment of hepatic fibrosis induced by hepatolenticular degeneration[J]. Genet Mol Res, 2017, 16(1).
[13] Zong Y N, Kong X D. Analysis and application of atp7b gene mutations in 35 patients with hepatolenticular degeneration[J]. Genet Mol Res, 2015, 14(4): 18764-18770.
[14] Wooton-Kee C R. Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson′s disease[J]. Pharmacol Ther, 2023: 108529.
[15] Liang Q S, Xie J G, Yu C, et al. Splenectomy improves liver fibrosis via tumor necrosis factor superfamily 14 (LIGHT) through the JNK/TGF-β1 signaling pathway[J]. Exp Mol Med, 2021, 53(3):393-406.
[16] Elchaninov A, Vishnyakova P, Gantsova E, et al. Cellular effects of splenectomy on liver regeneration after 70% resection[J]. Front Cell Dev Biol, 2025, 13:1561815.
[17] Li M, Li F, Luo C, et al. Immediate splenectomy decreases mortality and improves cognitive function of rats after severe traumatic brain injury[J]. J Trauma, 2011, 71(1):141-147.